2021 CHEO Conference: Lingrui Pharmaceutical was elected as a "Top 100 Enterprise in Comprehensive Competitiveness Index of Pharmaceutical Industry" as well as a part of the “Top 50 Companies in Chinese Patent Medicine of Pharmaceutical Industry Comprehensive Competitiveness Index”
The 2021 CHEO Conference was held at the Boao Asia Forum Hotel in Hainan Province from September 23rd to 28th. CHEO, abbreviated from the full name of China Health (International) Ecology Organization is sponsored by Zhongkang Technology. A forward-looking industry conference with the highest specifications, it boasts the largest scale as well as having one of the strongest influences in China's health industry.
On September 25, 2021, Zhongkang Technology authoritatively released the CHEO Index at the conference, namely the 2020-2021 Pharmaceutical Industry Development Index as well as the Pharmaceutical Industry Comprehensive Competitiveness Index.
Currently compiled and published by Zhongkang Technology, the CHEO lndex describes data obtained by establishing a unified standardized evaluation model through continuous monitoring of industrial economic operation. It also takes into account the most competitive and influential core indicators of enterprise and brand clusters in a specific period of time. This includes the pharmaceutical industry development index (including the comprehensive competitiveness index of the pharmaceutical industry), the pharmaceutical retail industry development index (including the comprehensive competitiveness index of pharmaceutical retail enterprises) and the health industry۰ brand development index tri-series of index components. It comprehensively, intuitively, and objectively reflects the development of the industry and the competitiveness of the enterprise in question.
The pharmaceutical industry development index assesses the overall growth trend of the pharmaceutical industry and the fluctuation of core operating indicators. Taking into account the four dimensions of "industry investment, revenue level, profitability, and export trade", the comprehensive competitiveness index of the pharmaceutical industry reflects the comprehensive competitiveness of China's domestic pharmaceutical industry companies based on the six-force model of "commercialization, R&D, product, brand, productivity, and profitability".
Lingrui Pharmaceutical was elected as one of the "Top 100 Enterprises in Comprehensive Competitiveness Index of Pharmaceutical Industry" and “Top 50 Companies in Chinese Patent Medicine of Pharmaceutical Industry Comprehensive Competitiveness Index”. Lingrui was also awarded the "Health Industry ∙ Brand Development Index Top Brand" distinction. This is the 12th consecutive year that the Lingrui brand has won this award.